Veracyte is a company that is creating solutions to improve traditional diagnostic methods and clinical outcomes for patients. The company was founded in 2008, in San Francisco, California, United States.
The company has developed genomic diagnostic tests that are designed to provide physicians and patients with paths forward. Their tests are equipped with machine learning that provides diagnostics, prognostic and treatment options. The tests can be used to determine what a patient should do after diagnosed with thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis.
Veracyte has developed their products Afirma, Percepta, Envisia, and Prosigna to reduce uncertainties and risks in diagnostics. Afirma is a genomic sequencing classifier that was developed with RNA whole-transcriptome sequencing and machine learning, and was designed to identify benign thyroid nodules. Percepta is also a genomic sequencing classifier, and identifies lung cancer. Prosignia uses genomic technology to identify breast cancer and the make-up of a patient's disease. Envisia is Veracyte's product that diagnoses idiopathic pulmonary fibrosis.
